1-甲基-1H-吲唑-3-胺 | 60301-20-4

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 1-甲基-1H-吲唑-3-胺
• 中文别名: 1-甲基-3-氨基吲唑；3-氨基-1-甲基-1H-吲唑
• 英文名称: 1-methyl-1H-indazol-3-amine
• 英文别名: 3-amino-1-methyl-1H-indazole；1-methylindazol-3-amine；3-Amino-1-methyl-indazol
• CAS: 60301-20-4
• 化学式: C₈H₉N₃
• mdl: MFCD09054755
• 分子量: 147.18
• InChiKey: NYLGITXFVVEBLZ-UHFFFAOYSA-N

物化性质

• 熔点：
  85-88°
• 沸点：
  321.6±15.0 °C(Predicted)
• 密度：
  1.27±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H317,H319
• 储存条件：
  室温、避光、干燥、密封保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
1-Methylindazol-3-amine
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
1-Methylindazol-3-amine
Ingredient name:
CAS number: 60301-20-4

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H9N3
Molecular weight: 147.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-甲基-1H-吲唑-3-胺 在 亚硝酸特丁酯 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以86%的产率得到1-甲基吲唑
  参考文献：
  名称：

  A method for the regioselective synthesis of 1-alkyl-1H-indazoles

  摘要：

  A method for the regioselective synthesis of 3-unsubstituted 1-alkyl-1H-indazoles, starting with 2-halobenzonitriles and N-alkylhydrazines, is described. The two-step reaction pathway proceeds through the intermediacy of 1-alkyl-3-amino-1H-indazoles followed by reductive deamination. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2013.03.042
• 作为产物：
  描述：

  3-氨基吲唑 在 potassium carbonate 、 肼 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.5h， 生成 1-甲基-1H-吲唑-3-胺
  参考文献：
  名称：

  WO2008/77188

  摘要：

  公开号：
• 作为试剂：
  描述：

  ethyl 3-(dimethylamino)acrylate 、 二氟溴乙酸乙酯 、 对甲苯磺酰肼 在 [Ir(dF(CF₃)ppy)₂(dtbbpy)](PF₆) 、 水 、 1-甲基-1H-吲唑-3-胺 作用下， 以 二甲基亚砜 为溶剂， 以74 %的产率得到diethyl 1-tosyl-1H-pyrazole-4,5-dicarboxylate
  参考文献：
  名称：

  1,3,4- 和 1,4,5-三取代吡唑的区域选择性-可切换形式 [1 + 2 + 2] 环加成反应中的无痕杂环胺介体

  摘要：

  可切换的多组分反应已成为通过稍微改变反应条件来构建具有骨架多样性和复杂性的化合物库的有吸引力的工具。本文描述的是二氟烷基化合物、烯胺酮和 RNHNH 2的区域选择性可切换形式 [1 + 2 + 2] 环加成反应，最终使用 1-methylindazol-3-amine 作为无痕介质来切换 1,3 的固有区域选择性， 4-三取代吡唑形成1,4,5-三取代吡唑。这项工作的显着特点是条件温和、操作简单、适用范围广。

  DOI：

  10.1021/acs.orglett.2c04227

文献信息

• 2-吡啶取代脲结构小分子化合物及其合成和应用
  申请人：中国科学院上海药物研究所

  公开号：CN110818683B

  公开（公告）日：2023-04-14

  本发明涉及2‑吡啶取代脲结构小分子化合物及其合成和应用。具体地，本发明公开了式(I)所述的化合物，其对映异构体、非对映异构体、外消旋体或其混合物，或其药学上可接受的盐、水合物及溶剂合物及其制备方法和在制备ASK1小分子抑制剂，或预防和/或治疗与ASK1相关疾病，尤其是肝脏疾病、肺部疾病、心血管疾病、肾脏疾病和代谢性疾病的药物中的用途。
• A General, One-Step Synthesis of Substituted Indazoles using a Flow Reactor
  作者：Rob C. Wheeler、Emma Baxter、Ian B. Campbell、Simon J. F. Macdonald

  DOI：10.1021/op100288t

  日期：2011.5.20

  Flow chemistry is a rapidly emerging technology within the pharmaceutical industry, both within medicinal and development chemistry groups. The advantages of flow chemistry, increased safety, improved reproducibility, enhanced scalability, are readily apparent, and we aimed to exploit this technology in order to provide small amounts of pharmaceutically interesting fragments via a safe and scalable

  流动化学是医药工业中快速发展的技术，无论是在药物化学领域还是在发展化学领域。流动化学的优点，增加的安全性，改进的可重复性，增强的可扩展性显而易见，我们的目标是利用这一技术，以通过安全且可扩展的途径提供少量可药用的片段，从而实现快速合成。需求量为多克。在这里，我们报告了一种通用且通用的途径，该途径利用流动化学来提供一系列已知的和新颖的吲唑，包括3-氨基和3-羟基类似物。
• [EN] KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE KYNURÉNINE-3-MONOOXYGÉNASE, COMPOSITIONS PHARMACEUTIQUES ET PROCÉDÉS D'UTILISATION DE CES COMPOSITIONS
  申请人：COURTNEY STEPHEN MARTIN

  公开号：WO2013033068A1

  公开（公告）日：2013-03-07

  Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

  本文提供了某些化学实体。还提供了包括至少一种化学实体和一种或多种药用可接受载体的药物组合物。描述了治疗对KMO活性抑制敏感的某些疾病和疾病的方法，包括向这些患者施用至少一种化学实体的有效量以减少疾病或疾病的体征或症状。这些疾病包括亨廷顿病等神经退行性疾病。还描述了治疗方法，包括将至少一种化学实体作为单一活性剂或将至少一种化学实体与一种或多种其他治疗剂结合使用。还提供了筛选能够抑制KMO活性的化合物的方法。
• TRPV1 Antagonists
  申请人：Gomtsyan Arthur

  公开号：US20120245163A1

  公开（公告）日：2012-09-27

  Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, solvates, or combinations thereof, wherein X 1 , X 2 , X 3 , X 4 , J, K, L, X 5 , X 6 , R b , G 2 , and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

  本文揭示了具有以下式（I）的化合物或药用可接受的盐、溶剂或其组合物，其中X1、X2、X3、X4、J、K、L、X5、X6、Rb、G2和m在规范中有定义。还披露了包含这些化合物的组合物以及使用这些化合物和组合物治疗疾病和疾病的方法。
• Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins
  作者：Deheng Chen、Tian Lu、Ziqin Yan、Wenchao Lu、Feilong Zhou、Xilin Lyu、Biling Xu、Hualiang Jiang、Kaixian Chen、Cheng Luo、Yujun Zhao

  DOI：10.1016/j.ejmech.2019.111633

  日期：2019.11

  Recently, selective inhibition of BET BD2 is emerging as a promising strategy for drug discovery. Despite significant progress in this area, systematic studies of selective BET BD2 inhibitors are still few. In this study, we report the discovery of a potent and selective BET BD2 inhibitor BY27 (47). Our high resolution co-crystal structures of 47/BRD2 BD1 and BD2 showed that the triazole group of 47

  最近，对BET BD2的选择性抑制正在成为一种有前途的药物发现策略。尽管在该领域取得了重大进展，但选择性BET BD2抑制剂的系统研究仍然很少。在这项研究中，我们报告了一种有效且选择性的BET BD2抑制剂BY27的发现（47）。我们的高分辨率共晶体结构47 / BRD2 BD1和BD2显示，BRD2 BD2中的47，水分子，H433和N429的三唑基建立了水桥H键网络，这是观察到的选择性的原因。用47或OTX015处理的HepG2细胞的DNA微阵列分析表明，BET BD2选择性抑制剂和pan BET抑制剂之间的转录组影响差异。在MV4-11小鼠异种移植模型中，47在大剂量时可引起67％的肿瘤生长抑制，且毒性比pan BET抑制剂1低。我们得出结论，选择性BET BD2抑制剂的改善的安全性值得在BET相关疾病中进行进一步的研究。